Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores

NCT03797612 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study initiation delayed due to COVID 19

Conditions

Pain, Postoperative

Interventions

DRUG: Brivoligide Injection 660 mg/6 mL
DRUG: Placebo 6 mL

Sponsor

Adynxx, Inc.